PALATIN TECHNOLOGIES INC
PTN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PTN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PTN
Palatin Technologies is a biopharmaceutical company focused on developing melanocortin receptor agonists for rare MC4R pathway diseases and ocular conditions, with a recent partnership with Boehringer Ingelheim and a public offering to extend its cash runway.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 5 pipeline candidates · 1 clinical trial for PALATIN TECHNOLOGIES INC.
Palatin Technologies is a biopharmaceutical company focused on developing melanocortin receptor agonists for rare MC4R pathway diseases and ocular conditions, with a recent partnership with Boehringer Ingelheim and a public offering to extend its cash runway.
- Cash and cash equivalents were $10.2M as of 2026-03-31 [sec].
- Total revenue was $3.9M and net income was -$1.4M for the period ending 2026-03-31 [sec].
- Shareholders' equity was -$4.8M as of 2026-03-31 [sec].
- In August 2025, Palatin entered into a research collaboration with Boehringer Ingelheim for melanocortin receptor-targeted compounds for retinal diseases [sec · filed 2026-06-25].
- The company closed a public offering in November 2025, raising $18M in net proceeds [sec · filed 2026-06-25].
What works
- Palatin has a strategic partnership with Boehringer Ingelheim for melanocortin receptor-targeted compounds in retinal diseases, providing non-dilutive funding and development expertise [sec · filed 2026-06-25].
- The company has a pipeline of MC4R agonists for rare MC4R pathway diseases, with multiple clinical trials planned in calendar year 2026 [sec_mda · as of 2026-02-17].
- Palatin has out-licensed or is available to out-license several programs, potentially generating milestone payments and royalties [sec_mda · as of 2026-02-17].
- The company expects existing cash to fund operations through the next twelve months following the issuance of financial statements [sec_mda · as of 2026-05-13].
What to weigh
- Palatin has incurred cumulative negative cash flows from operations since inception and has no recurring source of revenue after selling Vyleesi rights [sec_mda · as of 2026-02-17].
- The company will need additional funding to complete required clinical trials and regulatory submissions, which is uncertain [sec_mda · as of 2026-05-13].
- Shareholders' equity is negative at -$4.8M as of 2026-03-31, indicating accumulated deficits [sec].
- Current economic conditions, including high interest rates and inflation, may negatively impact operations and funding availability [sec_mda · as of 2026-02-17].
From the filings
Quoted directly from source documents.
Palatin entered into a collaboration with Boehringer Ingelheim in August 2025.
“In August 2025, we entered into a Research Collaboration, License and Patent Assignment Agreement with Boehringer-Ingelheim International GmbH to research, develop and commercialize first-in-class melanocortin receptor-targeted compounds we developed for the treatment of retinal diseases.”
SEC filings · June 25, 2026
The company closed a public offering in November 2025 raising $18M.
“Financing Transaction-In November 2025, we closed on a public offering of $18.”
SEC filings · June 25, 2026
Palatin expects existing cash to fund operations for the next twelve months.
“Based on our current operating and development plans, including the ability to reduce or delay operating expenses that are within management's control, we expect that existing cash and cash equivalents as of the date of this filing will be sufficient to enable us to fund operations through the next twelve months following the issuance of the financial statements.”
SEC MD&A · May 13, 2026
The company has incurred cumulative negative cash flows from operations since inception.
“We have incurred cumulative negative cash flows from operations since our inception, and have expended substantial funds to advance our planned product development efforts.”
SEC MD&A · February 17, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Palatin has a history of negative cash flows and needs additional funding to continue operations beyond 12 months [sec_mda · as of 2026-05-13].
- Dependence on partnerships — The company relies on strategic alliances for development and funding; failure to secure partners could stall programs [sec_mda · as of 2026-02-17].
- Clinical trial uncertainty — Success of clinical trials for MC4R and ocular programs is unpredictable; failure could impair pipeline value [sec_mda · as of 2026-05-13].
- No recurring revenue — After selling Vyleesi rights, Palatin has no recurring revenue source, relying on milestones and financing [sec_mda · as of 2026-02-17].
What to watch
- Progress of MC4R agonist clinical trials planned for calendar year 2026 [sec_mda · as of 2026-02-17].
- Updates from the Boehringer Ingelheim collaboration on retinal disease compounds [sec · filed 2026-06-25].
- Cash runway and any additional financing or partnership announcements [sec_mda · as of 2026-05-13].
- Regulatory milestones for PL9643 sublicensed to Altanispac Labs [sec_mda · as of 2026-02-17].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PALATIN TECHNOLOGIES INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PALATIN TECHNOLOGIES INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
7.4 months
D/E 0.25 · 0% dilution
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$14.8M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 280,000 | $4.9M |
| driehaus capital management llc | 166,713 | $2.9M |
| perceptive advisors llc | 123,890 | $2.2M |
| ra capital management, l.p. | 70,000 | $1.2M |
| balyasny asset management l.p. | 41,169 | $717K |
| vanguard capital management llc | 37,958 | $661K |
| superstring capital management lp | 35,969 | $627K |
| morgan stanley | 27,272 | $475K |
| geode capital management, llc | 18,502 | $322K |
| miller financial services llc | 12,600 | $219K |
Showing top 10 of 25 institutional holders of PALATIN TECHNOLOGIES INC. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 8.3%
- Days to cover
- 10.5
- Shares short
- 145,791
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PTN short interestGovernance
Frequently asked questions
What is the AI investment thesis for PALATIN TECHNOLOGIES INC?
Palatin Technologies is a biopharmaceutical company focused on developing melanocortin receptor agonists for rare MC4R pathway diseases and ocular conditions, with a recent partnership with Boehringer Ingelheim and a public offering to extend its cash runway.
What is PALATIN TECHNOLOGIES INC's lead drug candidate?
PALATIN TECHNOLOGIES INC's most advanced tracked candidate is bremelanotide (Preclinical) for Erectile Dysfunction.
Who is the CEO of PALATIN TECHNOLOGIES INC?
Dr. Carl Spana Ph.D. is the chief executive officer of PALATIN TECHNOLOGIES INC (PTN).
Where is PALATIN TECHNOLOGIES INC headquartered?
PALATIN TECHNOLOGIES INC (PTN) is headquartered in Monmouth Junction, NJ, United States.
What therapeutic areas does PALATIN TECHNOLOGIES INC focus on?
PALATIN TECHNOLOGIES INC develops therapies across Rare Disease, Immunology, Ophthalmology, Cardiovascular, Metabolic, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.